Patents by Inventor William Boulanger

William Boulanger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Copper (I) complexes with glycine, pyruvate, and succinate
    Patent number: 10596193
    Abstract: The present invention is directed to a pharmaceutical and/or dietary supplement composition comprising an effective amount of a copper (I) complex with glycine, pyruvate, or succinic acid and methods of treating mitochondrial, neuromuscular, and other diseases. Also provided are pharmaceutical treatment regimes and kits comprising a copper (I) complex with glycine, pyruvate, or succinate.
    Type: Grant
    Filed: September 15, 2017
    Date of Patent: March 24, 2020
    Assignee: C Lab Pharma International, S.A.
    Inventors: Charles Louis Albartus Barker, William A. Boulanger
  • COPPER (I) COMPLEXES WITH GLYCINE, PYRUVATE, AND SUCCINATE
    Publication number: 20180071336
    Abstract: The present invention is directed to a pharmaceutical and/or dietary supplement composition comprising an effective amount of a copper (I) complex with glycine, pyruvate, or succinic acid and methods of treating mitochondrial, neuromuscular, and other diseases. Also provided are pharmaceutical treatment regimes and kits comprising a copper (I) complex with glycine, pyruvate, or succinate.
    Type: Application
    Filed: September 15, 2017
    Publication date: March 15, 2018
    Inventors: Charles Louis Albartus Barker, William A. Boulanger
  • Chlorite formulations, and methods of preparation and use thereof
    Patent number: 9839650
    Abstract: Described herein are chlorite formulations having a pH between about 7 and about 8.5, wherein the chlorite formulations are substantially free of deleterious non-chlorite components. Described herein are chlorite formulations, including pharmaceutical formulations, which are formulated for systemic, parenteral, or intravenous administration. Described herein are methods of preparing and methods of using the chlorite formulations described herein.
    Type: Grant
    Filed: January 15, 2016
    Date of Patent: December 12, 2017
    Assignee: NEURALTUS PHARMACEUTICALS, INC.
    Inventors: William Boulanger, Arasteh Ari Azhir
  • CHLORITE FORMULATIONS, AND METHODS OF PREPARATION AND USE THEREOF
    Publication number: 20160129040
    Abstract: Described herein are chlorite formulations having a pH between about 7 and about 8.5, wherein the chlorite formulations are substantially free of deleterious non-chlorite components. Described herein are chlorite formulations, including pharmaceutical formulations, which are formulated for systemic, parenteral, or intravenous administration. Described herein are methods of preparing and methods of using the chlorite formulations described herein.
    Type: Application
    Filed: January 15, 2016
    Publication date: May 12, 2016
    Inventors: William BOULANGER, Arasteh Ari AZHIR
  • Chlorite formulations and methods of preparation and use thereof
    Patent number: 9266734
    Abstract: Described herein are chlorite formulations having a pH between about 7 and about 8.5, wherein the chlorite formulations are substantially free of deleterious non-chlorite components. Described herein are chlorite formulations, including pharmaceutical formulations, which are formulated for systemic, parenteral, or intravenous administration. Described herein are methods of preparing and methods of using the chlorite formulations described herein.
    Type: Grant
    Filed: September 29, 2011
    Date of Patent: February 23, 2016
    Assignee: NEURALTUS PHARMACEUTICALS, INC.
    Inventors: William Boulanger, Arasteh Ari Azhir
  • COPPER (I) COMPLEXES WITH GLYCINE, PYRUVATE, AND SUCCINATE
    Publication number: 20160024118
    Abstract: The present invention is directed to a pharmaceutical and/or dietary supplement composition comprising an effective amount of a copper (I) complex with glycine, pyruvate, or succinate and methods of treating mitochondrial, neuromuscular, and other diseases. Also provided are pharmaceutical treatment regimes and kits comprising a copper (I) complex with glycine, pyruvate, or succinate.
    Type: Application
    Filed: March 7, 2014
    Publication date: January 28, 2016
    Inventors: Charles Louis Albartus Barker, William A. Boulanger
  • Chlorite formulations and methods of preparation and use thereof
    Patent number: 8501244
    Abstract: Described herein are chlorite formulations having a pH between about 7 and about 8.5, wherein the chlorite formulations are substantially free of deleterious non-chlorite components. Described herein are chlorite formulations, including pharmaceutical formulations, which are formulated for systemic, parenteral, or intravenous administration. Described herein are methods of preparing and methods of using the chlorite formulations described herein.
    Type: Grant
    Filed: September 29, 2011
    Date of Patent: August 6, 2013
    Assignee: Neuraltus Pharmaceuticals, Inc.
    Inventors: William Boulanger, Arasteh Ari Azhir
  • Process for and intermediates in the preparation of canfosfamide and its salts
    Patent number: 8334266
    Abstract: A process for and intermediates in the preparation of canfosfamide and its salts. Some of the intermediates have anticancer activity.
    Type: Grant
    Filed: March 23, 2012
    Date of Patent: December 18, 2012
    Assignee: Telik, Inc.
    Inventors: William A. Boulanger, Steven J. Collier, Stephen A. Eastham, Dennis L. Edie, Ronan Y. Guevel, Pedro E. Hernandez Abad, R. Jason Herr, Hans J. Kjaersgaard, Harold Meckler, Robert E. Polomski, Steven R. Schow, Pavel E. Zhichkin
  • PROCESS FOR AND INTERMEDIATES IN THE PREPARATION OF CANFOSFAMIDE AND ITS SALTS
    Publication number: 20120238772
    Abstract: A process for and intermediates in the preparation of canfosfamide and its salts. Some of the intermediates have anticancer activity.
    Type: Application
    Filed: March 23, 2012
    Publication date: September 20, 2012
    Inventors: William A. Boulanger, Steven J. Collier, Stephen A. Eastham, Dennis L. Edie, Ronan Y. Guevel, Pedro E. Hernández Abad, R. Jason Herr, Hans J. Kjaersgaard, Harold Meckler, Robert E. Polomski, Steven R. Schow, Pavel E. Zhichkin
  • Chlorite formulations and methods of preparation and use thereof
    Patent number: 8231856
    Abstract: Described herein are chlorite formulations having a pH between about 7 and about 8.5, wherein the chlorite formulations are substantially free of deleterious non-chlorite components. Described herein are chlorite formulations, including pharmaceutical formulations, which are formulated for systemic, parenteral, or intravenous administration. Described herein are methods of preparing and methods of using the chlorite formulations described herein.
    Type: Grant
    Filed: May 9, 2011
    Date of Patent: July 31, 2012
    Assignee: Neuraltus Pharmaceuticals, Inc.
    Inventors: William Boulanger, Arasteh Ari Azhir
  • Process for and intermediates in the preparation of canfosfamide and its salts
    Patent number: 8198247
    Abstract: A process for and intermediates in the preparation of canfosfamide and its salts. Some of the intermediates have anticancer activity.
    Type: Grant
    Filed: December 21, 2004
    Date of Patent: June 12, 2012
    Assignee: Telik, Inc.
    Inventors: William A. Boulanger, Dennis L. Edie, Ronan Y. Guevel, Pedro E. Hernandez Abad, R. Jason Herr, Harold Meckler, Steven R. Schow, Pavel E. Zhichkin
  • Chlorite Formulations and Methods of Preparation and Use Thereof
    Publication number: 20120021069
    Abstract: Described herein are chlorite formulations having a pH between about 7 and about 8.5, wherein the chlorite formulations are substantially free of deleterious non-chlorite components. Described herein are chlorite formulations, including pharmaceutical formulations, which are formulated for systemic, parenteral, or intravenous administration. Described herein are methods of preparing and methods of using the chlorite formulations described herein.
    Type: Application
    Filed: September 29, 2011
    Publication date: January 26, 2012
    Applicant: Neuraltus Pharmaceuticals, Inc.
    Inventors: William Boulanger, Arasteh Ari Azhir
  • Chlorite Formulations and Methods of Preparation and Use Thereof
    Publication number: 20120021070
    Abstract: Described herein are chlorite formulations having a pH between about 7 and about 8.5, wherein the chlorite formulations are substantially free of deleterious non-chlorite components. Described herein are chlorite formulations, including pharmaceutical formulations, which are formulated for systemic, parenteral, or intravenous administration. Described herein are methods of preparing and methods of using the chlorite formulations described herein.
    Type: Application
    Filed: September 29, 2011
    Publication date: January 26, 2012
    Applicant: Neuraltus Pharmaceuticals, Inc.
    Inventors: William Boulanger, Arasteh Ari Azhir
  • Chlorite Formulations and Methods of Preparation and Use Thereof
    Publication number: 20120015051
    Abstract: Described herein are chlorite formulations having a pH between about 7 and about 8.5, wherein the chlorite formulations are substantially free of deleterious non-chlorite components. Described herein are chlorite formulations, including pharmaceutical formulations, which are formulated for systemic, parenteral, or intravenous administration. Described herein are methods of preparing and methods of using the chlorite formulations described herein.
    Type: Application
    Filed: May 9, 2011
    Publication date: January 19, 2012
    Applicant: Neuraltus Pharmaceuticals, Inc.
    Inventors: William Boulanger, Arasteh Ari Azhir
  • Chlorite formulations, and methods of preparation and use thereof
    Patent number: 8067035
    Abstract: Described herein are chlorite formulations having a pH between about 7 and about 8.5, wherein the chlorite formulations are substantially free of deleterious non-chlorite components. Described herein are chlorite formulations, including pharmaceutical formulations, which are formulated for systemic, parenteral, or intravenous administration. Described herein are methods of preparing and methods of using the chlorite formulations described herein.
    Type: Grant
    Filed: December 21, 2006
    Date of Patent: November 29, 2011
    Assignee: Neuraltus Pharmaceuticals, Inc.
    Inventors: William Boulanger, Arasteh Ari Azhir
  • Chlorite Formulations, and Methods of Preparation and Use Thereof
    Publication number: 20070145328
    Abstract: Described herein are chlorite formulations having a pH between about 7 and about 8.5, wherein the chlorite formulations are substantially free of deleterious non-chlorite components. Described herein are chlorite formulations, including pharmaceutical formulations, which are formulated for systemic, parenteral, or intravenous administration. Described herein are methods of preparing and methods of using the chlorite formulations described herein.
    Type: Application
    Filed: December 21, 2006
    Publication date: June 28, 2007
    Inventors: William Boulanger, Arasteh Azhir
  • Process for and intermediates in the preparation of canfosfamide and its salts
    Publication number: 20060135409
    Abstract: A process for and intermediates in the preparation of canfosfamide and its salts. Some of the intermediates have anticancer activity.
    Type: Application
    Filed: December 21, 2004
    Publication date: June 22, 2006
    Inventors: William Boulanger, Steven Collier, Stephen Eastham, Dennis Edie, Ronan Guevel, Pedro Abad, R. Herr, Hans Kjaersgaard, Harold Meckler, Robert Polomski, Steven Schow, Pavel Zhichkin
  • Method for the preparation of (.+-.)-calanolide A and intermediates thereof
    Patent number: 6043271
    Abstract: A method of preparing (.+-.)-calanolide A, 1, a potent HIV reverse transcriptase inhibitor, from chromene 4 is provided. Useful intermediates for preparing (.+-.)-calanolide A and its derivatives are also provided. According to the disclosed method, chromene 4 intermediate was reacted with acetaldehyde diethyl acetal or paraldehyde in the presence of an acid catalyst with heating, or a two-step reaction including an aldol reaction with acetaldehyde and cyclization either under acidic conditions or neutral Mitsunobu conditions, to produce chromanone 7. Reduction of chromanone 7 with sodium borohydride, in the presence of cerium trichloride, produced (.+-.)-calanolide A. A method for resolving (.+-.)-calanolide A into its optically active forms by a chiral HPLC system or by enzymatic acylation and hydrolysis is also disclosed. Finally, a method for treating or preventing a viral infections using (.+-.)-calanolide or (-)-calanolide is provided.
    Type: Grant
    Filed: August 2, 1995
    Date of Patent: March 28, 2000
    Assignee: Sarawak MediChem Pharmaceuticals, Inc.
    Inventors: Michael T. Flavin, Ze-Qi Xu, John D. Rizzo, Alla Kucherenko, Albert Khilevich, Abram Kivovich Sheinkman, Vilayphone Vilaychack, Lin Lin, Wei Chen, William A. Boulanger
  • Method for the preparation of (.+-.)-calanolide A and intermediates thereof
    Patent number: 5869324
    Abstract: A method of preparing (.+-.)-calanolide A, 1, a potent HIV reverse transcriptase inhibitor, from chromene 4 is provided. Useful intermediates for preparing (.+-.)-calanolide A and its derivatives are also provided. According to the disclosed method, chromene 4 intermediate was reacted with acetaldehyde diethyl acetal or paraldehyde in the presence of an acid catalyst with heating, or a two-step reaction including an aldol reaction with acetaldehyde and cyclization either under acidic conditions or neutral Mitsunobu conditions, to produce chromanone 7. Reduction of chromanone 7 with sodium borohydride, in the presence of cerium trichloride, produced (.+-.)-calanolide A. A method for resolving (.+-.)-calanolide A into its optically active forms by a chiral HPLC system or by enzymatic acylation and hydrolysis is also disclosed. Finally, a method for treating or preventing viral infections using (.+-.)-calanolide A or (-)-calanolide A is provided.
    Type: Grant
    Filed: September 8, 1997
    Date of Patent: February 9, 1999
    Assignee: Sarawak MediChem Pharmaceuticals, Inc.
    Inventors: Michael T. Flavin, Ze-Qi Xu, John D. Rizzo, Alla Kucherenko, Albert Khilevich, Abram Kivovich Sheinkman, Vilayphone Vilaychack, Lin Lin, Wei Chen, William A. Boulanger
  • Method for the preparation of (+)-calanolide A and intermediates thereof
    Patent number: 5489697
    Abstract: A method for preparing (.+-.)-calanolide A, 1, a potent HIV reverse transcriptase inhibitor, from chromene 4 is provided. Useful intermediates for preparing (.+-.)-calanolide A and its derivatives are also provided.According to the disclosed method, chromene 4 intermediate was reacted with acetaldehyde diethyl acetal in the presence of an acid catalyst with heating to produce chromanone 7. Reduction of chromene 7 with sodium borohydride, in the presence of cerium trichloride, produced (.+-.)-calanolide A, which was purified chromatographically.
    Type: Grant
    Filed: August 3, 1994
    Date of Patent: February 6, 1996
    Assignee: MediChem Research, Inc.
    Inventors: William A. Boulanger, Michael T. Flavin, Alla Kucherenko, Abram K. Sheynkman